TrialClinical and vaccine immunology : CVI2014

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Sharon E Frey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.